Trial Profile

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DSG3-CAART (Primary) ; Resecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine; Immune globulin
Indications Pemphigus vulgaris
Focus Adverse reactions; First in man
Acronyms DesCAARTes; RESET-PV
Sponsors Cabaletta Bio

23 Mar 2026 dose-ranging durability data from the RESET-PV trial are anticipated throughout 2026, supplementing the initial low dose PV data without preconditioning that were previously presented.
17 Dec 2025 The protocol has been amended to addition in number of arms and change in interventional study model as Sequential Assignment and change in study phase 1 to phase1/2.
17 Dec 2025 Planned number of patients changed from 55 to 40.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com